All protocols
Immune / Anti-Inflammatory

Thymosin Alpha-1 Peptide Protocol & Dosing

Updated 2mo ago 6 min read 246+ helpful Calculator
Validity Score

Validity Score

81 Strong
Evidence 86
Community 70
Completeness 71
Actionability 80
Coverage 100
Penalty -0

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

Thymosin Alpha-1 is a thymus-derived immune modulator used in immunology. It is mainly discussed for infection support, hepatitis, and related immune-repair settings.

Evidence boundary

Human evidence exists and the interpretation should stay tied to immune indications. Research-vial handling is not the same as a product label.

Trial evidence

  • PMID 40599771 — Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
  • PMID 39648386 — Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
  • PMID 38308608 — Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
  • PMID 33076834 — The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.

Preparation and measurement

Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
SettingDoseDraw / measureFrequencyWeekly total
Conservative immune reference300 mcg6 U (0.06 mL)Once daily2.1 mg/week
Higher immune reference500 mcg10 U (0.1 mL)Once daily3.5 mg/week

Conservative immune reference

Dose
300 mcg
Draw / measure
6 U (0.06 mL)
Frequency
Once daily
Weekly total
2.1 mg/week

Higher immune reference

Dose
500 mcg
Draw / measure
10 U (0.1 mL)
Frequency
Once daily
Weekly total
3.5 mg/week

Weekly totals apply only during the active phase. These are reference rows, not a product label.

Titration rules

  • 300 mcg is the cautious start.

  • 500 mcg is the higher collected step.

  • Keep the schedule tied to the immune goal.

  • Do not turn it into a generic recovery peptide.

  • Infection or inflammation response

  • Tolerability

  • Injection-site reactions

Practical rules

  • Rotate sites.
Was this protocol helpful?
Share via
Supply & lot verification Availability and batch-linked COA records for Thymosin Alpha-1 Peptide Protocol & Dosing are tracked with the current supplier listings. View availability & COA →

Dosing Calculator

10 mg + 2 mL BAC · week 1 300 mcg
LIVE CALCULATIONvolume / concentration / draw
RP–CALC–01
DRAW AMOUNT6 units0.06 mL · U-100
Draw 6 units, equivalent to 0.06 milliliters.
Concentration5 mg/mL
Selected dose0.3 mg (300 mcg) = 6 units
Enter a desired amount in milligrams or micrograms.
05 Standard amounts
1–10 mg · 0.5 mg steps
06 Suggested doses Select a row
1 unit = 0.01 mL on a U-100 syringe. Values retain decimal precision; visual marks are not silently snapped.
07 cycle summary

Vials required for Cycle

Estimate how much material you need for a full cycle, including cycle length and the number of cycles you plan to run.

Cycle total —
Total required vials —
Total reconstitution —
Total BAC water —
08 projected levels

How the draws stack up

A first-order model of depot absorption and elimination, run on the draws and cadence above. Pick the half-life from whatever your own source documents — this page does not assume one per compound. A planning sketch — not a prediction for any compound or any individual.

Half-life

Modelled level across the cycle. Each spike is one draw.

Accumulation—steady state vs one draw
Peak-to-trough—inside one interval
Steady state—about 4 half-lives
Draws modelled—at this cadence
Vial yieldat the selected amount
Draws per vial—
Lasts—
Volume used—
Limiting factor—
Water matrixsame vial, same amount
WaterStrengthDraw
0.5 mL——
1 mL——
2 mL——
3 mL——
5 mL——

Research Protocols

Keep up to date with latest protocols, updates and offers

An occasional email when a new protocol lands or an existing one is revised. No more than once a month.